← Back to patent-cliff list
GRWD-5769
Tier C — Watch / tradeGRWD-5769
Grey Wolf Therapeutics Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：ERAP1
Indications (approved)：Neoplasm, Solid tumour
Regional status
US
Phase II
2024-06-01
EU
Phase II
2023-05-21
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of GRWD-5769?
Approved indications include: Neoplasm, Solid tumour.
When does the GRWD-5769 patent expire?
No public expiry year is available for GRWD-5769 yet; this page updates once verified.
How do I get a quote for GRWD-5769 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21